Wockhardt signs in-licensing pact with Crawford Healthcare of UK, Launches Vitix for vitiligo skin disorder
- Category: More News
- Published on Tuesday, 23 January 2007 02:00
- Hits: 5516
MUMBAI, India | Jan, 22 2007 | Pharmaceutical and biotechnology major Wockhardt Limited has signed an in-licensing agreement with Crawford Healthcare of UK to market Viticolor, a skin camouflage gel for topical application for vitiligo patients.
Vitiligo, popularly called leucoderma, is a skin disorder that affects three to four percent of Indian population.The licensing deal follows the launch of Vitix, a patented product from LSI of UK, for the treatment of vitiligo in the Indian market this week. “Viticolor will complement Vitix and further strengthen our Indian dermatology portfolio,” Wockhardt chairman Habil Khorakiwala said. “We bring to India new products that have proved their effectiveness in Europe and USA.”Viticolor’s effect is expected to last for almost a week compared to the currently available camouflages imported into India, which lasts for less than 24 hours. It is safe for long-term use and claims to improve quality of life index. It is already marketed in Europe, North America, Africa and South East Asia.As in the case of Vitix, Wockhardt will manufacture Viticolor in India from imported active ingredients. Viticolor will be launched in the second quarter of 2007 by Wockhardt’s dedicated dermatology team.Crawford Healthcare is a UK-based speciality pharmaceutical company dedicated to providing treatment for a range of skin conditions.Wockhardt Limited is an internationally approved pharmaceutical and biotechnology company having a strong and innovative research and development programme. Wockhardt has made four successful acquisitions in Europe, where it employs 800 people. It has a wholly-owned subsidiary in USA. Europe and USA together account for over half of Wockhardt’s sales.